Monopar Therapeutics Inc
MNPR
Get informed when a big investor buys or sells
+ FollowMarket Cap$721.62M
Close$
$8.32
93% downside
Current Fair Value
93% downsideOvervalued by 93% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $721.62 Million |
|---|---|
| Enterprise Value | $668.97 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.85 |
| Beta | 1.51 |
| Outstanding Shares | 8,542,450 |
Return
| Return on Equity | -2638.04% |
|---|---|
| Return on Assets | -2557.44% |
| Return on Invested Capital | -3138.12% |
Valuation & Multiples
| P/E Ratio | -46.03 |
|---|---|
| PEG | -39.49 |
| Price to Sales | - |
| Price to Book Ratio | 7.94 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.16 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.64
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
$-0.78
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 93.18%▲ 10.59% |
|---|---|
| Total Invested | $341.55M▼ 5.34% |
| Investors Holding | 82▲ 9.00% |
ESG Score
No data
About Monopar Therapeutics Inc
10 employeesMonopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validi...